Skip to main content

Table 3 Toxicity profile after treatment

From: A phase II study of Endostatin in combination with paclitaxel, carboplatin, and radiotherapy in patients with unresectable locally advanced non-small cell lung cancer

Complications 0 I II III IV III + IV, % (n)
%(n) % (n) % (n) % (n) % (n)
Hematological toxicities
 Anemia 32 (6) 26 (5) 32 (6) 11 (2) 0 11 (2)
 Leukopenia 21 (4) 32 (6) 26 (5) 16 (3) 5 (1) 21 (4)
 Neutropenia 16 (3) 32 (6) 26 (5) 21 (4) 5 (1) 26 (5)
 Thrombocytopenia 26 (5) 42 (8) 21 (4) 5 (1) 5 (1) 11 (2)
Non-hematological toxicities
 Nausea 37 (7) 37 (7) 16 (3) 11 (2) 0 11 (2)
 Vomiting 47 (9) 32 (6) 11 (2) 11 (2) 0 11 (2)
 Anorexia 53 (10) 26 (5) 11 (2) 5 (1) 5 (1) 11 (2)
 Hemorrhage 90 (17) 5 (1) 5 (1) 0 0 0
 Fatigue 37 (7) 32 (6) 26 (5) 5 (1) 0 5 (1)
 ALT/AST 89 (15) 16 (3) 5 (1) 0 0 0
 Arrhythmia 63 (12) 37 (7) 0 0 0 0
 Esophagitis 26 (5) 37 (7) 16 (4) 11 (2) 5 (1) 16 (3)
 Pneumonitis 21 (4) 26 (5) 26 (5) 26 (5) 0 26 (5)